- Home
- OSCR vs MIRM Comparison
OSCR vs MIRM Comparison
Compare OSCR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSCR | MIRM |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.2B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OSCR | MIRM |
|---|---|---|
| Price | $30.91 | $105.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $16.88 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 4.0M | 560.4K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $11,701,427,000.00 | $19,138,000.00 |
| Revenue This Year | $63.89 | $26.22 |
| Revenue Next Year | $5.30 | $22.04 |
| P/E Ratio | $14.68 | ★ N/A |
| Revenue Growth | ★ 27.50 | N/A |
| 52 Week Low | $10.69 | $53.39 |
| 52 Week High | $33.10 | $130.00 |
Technical Indicators
Market Signals| Indicator | OSCR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout OSCR Oscar Health Inc.
Oscar Health Inc is a healthcare technology company built around a full stack technology platform and a relentless focus on serving its members. It offers Individual & Family plans and health technology solutions that power the healthcare industry. Oscar operates as one segment to sell insurance to individuals, families and employees through the federal and state-run healthcare exchanges formed in conjunction with the Patient Protection and Affordable Care Act (ACA) and leverages its technology platform to provide services via its Oscar offering.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.